MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progressionRupesh Paudel, Marc Schmidt, Andrea Knorz et al.|Cell Death and Disease|2025Cited by 4
AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanomaRupesh Paudel, Marc Schmidt, Simon Goller et al.|Neoplasia|2026Cited by 0